Pfizer Inc. (NYSE: PFE) has experienced a dramatic decline in its stock price, plummeting 63% from its all-time high. With the dividend yield now approaching 8%, many investors are evaluating whether this is a lucrative buying opportunity or a potential trap.

When it comes to the pharmaceutical industry, Pfizer stands tall as a legacy company with a rich history of innovation. However, its recent financial performance and stock price movements have left investors questioning its valuation. At a market cap of $124 billion and a trading price of $22 per share, is Pfizer undervalued, or does the dip signal deeper challenges?

Pfizer was a major player in the development of the Covid-19 vaccines, but are they a good investment now?

We kicked off September in style!  The stock market finally dropped for the week.  The S&P 500 finished down 3.91% and is now well below 5,500. 

Pfizer, the world top class company, develops and manufactures drugs or medicine and vaccines, having approximately 3.7 billion shares on NASDAQ.

3 Recession Proof Stocks with Low Volatility. The world is experiencing a wide range of macro troubles right now.